Analytical Validation of Quantitative Polymerase Chain Reaction and AscentTM Low-Pass Whole Genome Sequencing to Report on Gene Copy Number Variants in Cerebrospinal Fluid Tumor-Derived DNA
Journal of Molecular Pathology · 12.05.2026 · 7 (2) · 18
DOI: 10.3390/jmp7020018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Pathology, online erschienen am 12.05.2026. Verfasst von Viriya Keo und 11 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Background
Evaluation of gene-level copy number variants (CNVs) for diagnosis and therapeutic decision making has become standard of care with next-generation sequencing (NGS), immunohistochemistry (IHC), and/or fluorescence in situ hybridization (FISH) being used to detect gene amplifications/deletions in tumor tissue. In contrast to most solid tumors, CNS cancers are challenging to evaluate by resection and/or biopsy due to the associated risks with invasive brain surgery that can also result in death or associated morbidity and therefore alternate methods are required.
Methods
This study presents the analytical validation of using quantitative PCR (qPCR) to detect gene CNVs directly from cerebrospinal fluid (CSF)-derived DNA and from the AscentTM low-pass whole genome sequencing (LP-WGS) libraries, demonstrating concordance with the gold standard of NGS/IHC/FISH used in tumor tissue.
Results
The analytical sensitivity of qPCR to detect gene amplification calls for ERBB2 (erb-b2 receptor tyrosine kinase 2) was demonstrated to be 100% and that of EGFR (epidermal growth factor receptor) was 83%, with specificities of 96% and 100%, respectively. The analytical sensitivity of qPCR to detect gene deletions for CDKN2A/2B (cyclin-dependent kinase inhibitor 2A/2B) was 60% and that for MTAP (methylthioadenosine phosphorylase) was 100% with a specificity of 100% for all three genes. AscentTM was demonstrated to have a higher sensitivity (100%) when compared to qPCR for the same genes evaluated and demonstrated 100% positive agreement and 100% negative agreement with known CNV status.
Conclusions
The results demonstrate that given the paucity of cells in CSF limiting the use of IHC and FISH, qPCR and AscentTM provide highly sensitive, novel, minimally invasive methods for the evaluation of gene copy number (CN) status to inform the diagnosis and management of CNS cancers.
Förderung
- National Institutes of Health
Zitieren
APA
Keo, V., Khurana, S., Udhane, V., Larson, A., Adams, J. N., Sanchez, D., Peltier, T., Acevedo, A., Mitchell, K., Schilter, K. F., Nie, Q., & Reddi, H. V. (2026). Analytical Validation of Quantitative Polymerase Chain Reaction and AscentTM Low-Pass Whole Genome Sequencing to Report on Gene Copy Number Variants in Cerebrospinal Fluid Tumor-Derived DNA. Journal of Molecular Pathology, 7(2), 18. https://doi.org/10.3390/jmp7020018
Vancouver
Keo V, Khurana S, Udhane V, Larson A, Adams JN, Sanchez D, et al. Analytical Validation of Quantitative Polymerase Chain Reaction and AscentTM Low-Pass Whole Genome Sequencing to Report on Gene Copy Number Variants in Cerebrospinal Fluid Tumor-Derived DNA. Journal of Molecular Pathology. 2026;7(2):18. doi:10.3390/jmp7020018
BibTeX
@article{Keo2026,
author = {Keo, Viriya and Khurana, Sakshi and Udhane, Vindhya and Larson, Alexandra and Adams, Jennifer N. and Sanchez, Daniel and Peltier, Tarin and Acevedo, Anthony and Mitchell, Kathleen and Schilter, Kala F. and Nie, Qian and Reddi, Honey V.},
title = {Analytical Validation of Quantitative Polymerase Chain Reaction and AscentTM Low-Pass Whole Genome Sequencing to Report on Gene Copy Number Variants in Cerebrospinal Fluid Tumor-Derived DNA},
journal = {Journal of Molecular Pathology},
year = {2026},
volume = {7},
number = {2},
pages = {18},
doi = {10.3390/jmp7020018}
}
EUVIMED